Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590851 | 0.84 | SIGMAR1 (0.48) | FFAR1SIGMAR1TMEM97OPRL1ALDH1A1 | |
| SCHEMBL1966477 | 0.76 | SIGMAR1 (0.61) | SIGMAR1TMEM97OPRL1ALDH1A1POLB | |
| SCHEMBL19770185 | 0.74 | ALDH1A1 (0.62) | SIGMAR1OPRL1ALDH1A1POLBCYP3A4 | |
| SCHEMBL6825503 | 0.74 | FFAR4 (0.54) | FFAR1SIGMAR1TMEM97OPRL1ALDH1A1 | |
| SCHEMBL266138 | 0.72 | NPC1 (0.71) | SIGMAR1ALDH1A1 | |
| SCHEMBL7852213 | 0.72 | SIGMAR1 (0.53) | SIGMAR1TMEM97OPRL1ALDH1A1POLB | |
| SCHEMBL1975664 | 0.72 | SLC6A2 (0.60) | SIGMAR1TMEM97OPRL1ALDH1A1CYP3A4 | |
| SCHEMBL6823088 | 0.72 | SIGMAR1 (0.50) | FFAR1SIGMAR1TMEM97OPRL1ALDH1A1 | |
| SCHEMBL17611770 | 0.72 | CHRM2 (0.69) | SIGMAR1CHRM2CHRM3OPRM1CYP2D6 | |
| SCHEMBL11686136 | 0.71 | SIGMAR1 (0.68) | SIGMAR1TMEM97OPRL1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719384-A2 | COMPOUNDS WITH ANTIFUNGAL PROPERTIES | Trustees of Dartmouth College (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249290-A2 | COMPOUNDS WITH ANTIFUNGAL PROPERTIES | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2019238633-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | FFAR1 909/4885SIGMAR1 196/4885TMEM97 141/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | FFAR1 974/4885SIGMAR1 238/4885TMEM97 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.